Erratum To: Effect of Neoadjuvant Chemotherapy on Tumor-infiltrating Lymphocytes and PD-L1 Expression in Breast Cancer and Its Clinical Significance

Overview

Journal Breast Cancer Res

Specialty Oncology

Date 2017 Sep 27

PMID 28946899

Citations 2

Authors

Vasiliki Pelekanou

Daniel E Carvajal-Hausdorf

Mehmet Altan

Brad Wasserman

Cristobal Carvajal-Hausdorf

Hallie Wimberly

Jason Brown

Donald Lannin

Lajos Pusztai

David L Rimm

Affiliations

Soon will be listed here.

Citing Articles

A non-inferiority, phase III trial of gemcitabine plus capecitabine gemcitabine plus carboplatin as first-line therapy and tumor-infiltrating lymphocytes as a prognostic biomarker in patients with advanced triple-negative breast cancer.

Liu X, Zhao W, Jia Y, Shi Y, Wang X, Li S Ther Adv Med Oncol. 2024; 16:17588359241240304.

PMID: 39634173 PMC: 11615979. DOI: 10.1177/17588359241240304.

Immune contexture analysis in immuno-oncology: applications and challenges of multiplex fluorescent immunohistochemistry.

Shakya R, Nguyen T, Waterhouse N, Khanna R Clin Transl Immunology. 2020; 9(10):e1183.

PMID: 33072322 PMC: 7541822. DOI: 10.1002/cti2.1183.

References

Pelekanou V, Carvajal-Hausdorf D, Altan M, Wasserman B, Carvajal-Hausdorf C, Wimberly H . Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance. Breast Cancer Res. 2017; 19(1):91. PMC: 5547502. DOI: 10.1186/s13058-017-0884-8. View